MY207302A - Pharmaceutical compositions comprising rpl554 in hfa-134a for administration by inhalation - Google Patents
Pharmaceutical compositions comprising rpl554 in hfa-134a for administration by inhalationInfo
- Publication number
- MY207302A MY207302A MYPI2021001479A MYPI2021001479A MY207302A MY 207302 A MY207302 A MY 207302A MY PI2021001479 A MYPI2021001479 A MY PI2021001479A MY PI2021001479 A MYPI2021001479 A MY PI2021001479A MY 207302 A MY207302 A MY 207302A
- Authority
- MY
- Malaysia
- Prior art keywords
- rpl554
- hfa
- inhalation
- administration
- pharmaceutical compositions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Otolaryngology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1816447.5A GB2578093B (en) | 2018-10-09 | 2018-10-09 | Liquid pharmaceutical composition comprising RPL554 and HFA-134A |
| PCT/GB2019/052863 WO2020074894A1 (en) | 2018-10-09 | 2019-10-09 | Pharmaceutical compositions comprising rpl554 in hfa-134a for administration by inhalation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY207302A true MY207302A (en) | 2025-02-15 |
Family
ID=64394831
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI2021001479A MY207302A (en) | 2018-10-09 | 2019-10-09 | Pharmaceutical compositions comprising rpl554 in hfa-134a for administration by inhalation |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US20210379053A1 (enExample) |
| EP (2) | EP3820446B1 (enExample) |
| JP (2) | JP7578587B2 (enExample) |
| CN (1) | CN112912064B (enExample) |
| AU (1) | AU2019358585B2 (enExample) |
| BR (1) | BR112021006712A2 (enExample) |
| CA (1) | CA3113167A1 (enExample) |
| CY (1) | CY1124943T1 (enExample) |
| DK (1) | DK3820446T3 (enExample) |
| ES (1) | ES2899744T3 (enExample) |
| GB (1) | GB2578093B (enExample) |
| HR (1) | HRP20220053T1 (enExample) |
| HU (1) | HUE057780T2 (enExample) |
| IL (1) | IL282032B1 (enExample) |
| LT (1) | LT3820446T (enExample) |
| MX (2) | MX2021003599A (enExample) |
| MY (1) | MY207302A (enExample) |
| PH (1) | PH12021550767A1 (enExample) |
| PL (1) | PL3820446T3 (enExample) |
| PT (1) | PT3820446T (enExample) |
| RS (1) | RS62775B1 (enExample) |
| SG (1) | SG11202102567UA (enExample) |
| SI (1) | SI3820446T1 (enExample) |
| SM (1) | SMT202200044T1 (enExample) |
| WO (1) | WO2020074894A1 (enExample) |
| ZA (1) | ZA202102039B (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3231444T3 (pl) | 2014-05-12 | 2020-05-18 | Verona Pharma Plc | Nowe leczenie |
| GB201502260D0 (en) | 2015-02-11 | 2015-04-01 | Verona Pharma Plc | Salt of Pyrimido[6,1-A]Isoquinolin-4-one compound |
| GB201916915D0 (en) | 2019-11-20 | 2020-01-01 | Amr Centre Ltd | Compounds |
| GB2594480A (en) * | 2020-04-28 | 2021-11-03 | Verona Pharma Plc | New treatment |
| GB202202297D0 (en) | 2022-02-21 | 2022-04-06 | Verona Pharma Plc | Formulation production process |
| KR20250087621A (ko) * | 2022-10-28 | 2025-06-16 | 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 | 이소퀴놀리논계 화합물을 포함하는 약학적 조성물 및 이의 제조 방법 |
| EP4378942A1 (en) | 2022-12-02 | 2024-06-05 | Sandoz AG | Crystal form of a pde3/4 inhibitor |
| AU2024309346C1 (en) | 2023-06-26 | 2026-03-12 | Verona Pharma Plc | Particulate composition comprising ensifentrine |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60005493T2 (de) | 1999-03-31 | 2004-07-01 | Vernalis Ltd., Wokingham | Pyrimido[6,1-a]isochinolinonderivate |
| PH12013500261A1 (en) * | 2010-08-09 | 2013-03-04 | Verona Pharma Plc | Crystalline form of pyrimidio[6,1-a]isoquinolin-4-one compound |
| NZ629438A (en) * | 2012-02-28 | 2016-10-28 | Iceutica Holdings Inc | Inhalable pharmaceutical compositions |
| EP2968312B1 (en) * | 2013-03-15 | 2018-01-31 | Verona Pharma PLC | Drug combination |
| PL3231444T3 (pl) * | 2014-05-12 | 2020-05-18 | Verona Pharma Plc | Nowe leczenie |
| MY196072A (en) * | 2014-09-15 | 2023-03-13 | Verona Pharma Plc | Liquid Inhalation Formulation Comprising RPL554 |
| GB201502260D0 (en) * | 2015-02-11 | 2015-04-01 | Verona Pharma Plc | Salt of Pyrimido[6,1-A]Isoquinolin-4-one compound |
-
2018
- 2018-10-09 GB GB1816447.5A patent/GB2578093B/en active Active
-
2019
- 2019-10-09 AU AU2019358585A patent/AU2019358585B2/en active Active
- 2019-10-09 HR HRP20220053TT patent/HRP20220053T1/hr unknown
- 2019-10-09 CA CA3113167A patent/CA3113167A1/en active Pending
- 2019-10-09 LT LTEPPCT/GB2019/052863T patent/LT3820446T/lt unknown
- 2019-10-09 ES ES19790718T patent/ES2899744T3/es active Active
- 2019-10-09 MX MX2021003599A patent/MX2021003599A/es unknown
- 2019-10-09 SG SG11202102567UA patent/SG11202102567UA/en unknown
- 2019-10-09 BR BR112021006712-4A patent/BR112021006712A2/pt unknown
- 2019-10-09 EP EP19790718.1A patent/EP3820446B1/en active Active
- 2019-10-09 SI SI201930145T patent/SI3820446T1/sl unknown
- 2019-10-09 EP EP21198029.7A patent/EP3960157A1/en active Pending
- 2019-10-09 CN CN201980065895.8A patent/CN112912064B/zh active Active
- 2019-10-09 DK DK19790718.1T patent/DK3820446T3/da active
- 2019-10-09 HU HUE19790718A patent/HUE057780T2/hu unknown
- 2019-10-09 JP JP2021517866A patent/JP7578587B2/ja active Active
- 2019-10-09 US US17/280,452 patent/US20210379053A1/en not_active Abandoned
- 2019-10-09 SM SM20220044T patent/SMT202200044T1/it unknown
- 2019-10-09 RS RS20211599A patent/RS62775B1/sr unknown
- 2019-10-09 MY MYPI2021001479A patent/MY207302A/en unknown
- 2019-10-09 PL PL19790718T patent/PL3820446T3/pl unknown
- 2019-10-09 PT PT197907181T patent/PT3820446T/pt unknown
- 2019-10-09 WO PCT/GB2019/052863 patent/WO2020074894A1/en not_active Ceased
-
2021
- 2021-03-25 ZA ZA2021/02039A patent/ZA202102039B/en unknown
- 2021-03-26 MX MX2024001499A patent/MX2024001499A/es unknown
- 2021-04-04 IL IL282032A patent/IL282032B1/en unknown
- 2021-04-06 PH PH12021550767A patent/PH12021550767A1/en unknown
-
2022
- 2022-02-02 CY CY20221100086T patent/CY1124943T1/el unknown
-
2024
- 2024-03-26 US US18/616,878 patent/US20250049781A1/en active Pending
- 2024-06-05 JP JP2024091837A patent/JP7836853B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12021550767A1 (en) | Pharmaceutical compositions comprising rpl554 in hfa-134a for administration by inhalation | |
| PH12017500479B1 (en) | Liquid inhalation formulation comprising rpl554 | |
| MY123544A (en) | New inhalable powder containing tiotropium | |
| EP4548972A3 (en) | (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase i inhibitors | |
| MY121073A (en) | Pharmaceutical formulations for aerosols with two or more active substances | |
| MX2014004279A (es) | Composiciones que comprenden sulfato de salbutamol. | |
| UA107499C2 (uk) | Склад сухого порошку, який містить антимускариновий засіб | |
| GB201118188D0 (en) | Manufacture of medicinal aerosol canisters | |
| MY184654A (en) | Novel dosage form and formulation of abediterol | |
| MX2014004364A (es) | Composiciones que comprenden sulfato de salbutamol. | |
| PH12022550322A1 (en) | Pharmaceutical composition comprising ensifentrine | |
| ZA202303699B (en) | Processes and intermediate for the large-scale preparation of 2,4,6-trifluoro-n-[6-(1-methyl-piperidine-4-carbonyl)-pyridin-2-yl]-benzamide hemisuccinate, and preparation of 2,4,6-trifluoro-n-[6-(1-methyl-piperidine-4-carbonyl)-pyridin-2-yl]-benzamide acetate | |
| JOP20200314A1 (ar) | تركيبات صيدلانية مستقرة لأجهزة إستنشاق جرعات مضغوطة معايرة الجرعة | |
| MX370890B (es) | Composición que comprende sulfato de salbutamol. | |
| MX2017004476A (es) | Composicion que comprende al menos un polvo seco obtenido por secado por atomizacion para aumentar la estabilidad de la formulacion. | |
| MY145166A (en) | Novel tiotropium salts, process for the preparation and pharmaceutical compositions thereof | |
| MX2023003754A (es) | Formulacion farmaceutica para inhalador presurizado de dosis medidas. | |
| EP4400119A3 (en) | Cyclosporine formulations for use in the treatment of bronchiolitis obliterans syndrome (bos) | |
| EA201800266A1 (ru) | Антивирусная фармацевтическая композиция | |
| MY187442A (en) | A pharmaceutical composition containing budesonide and formoterol | |
| NZ599901A (en) | Improved medicinal aerosol formulations | |
| MY140890A (en) | New tiotropium containing powder formulation for inhalation | |
| JOP20220045A1 (ar) | تركيبة صيدلانية مائية من جسم مضاد ANTI-PD1 برولجوليماب prolgolimab واستخدامها | |
| MX2021014166A (es) | Composicion farmaceutica de compuesto de piridina amina y aplicacion de la misma en cancer de pulmon microcitico ros1 positivo. | |
| MX372705B (es) | Composición farmacéutica que contiene budesonida y formoterol |